Navigation Links
NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
Date:6/4/2011

*4 patients in the Q14 day arm with no post-baseline scans, but no evidence of progression were excluded from analysis in the evaluable population.

**based on a Kaplan-Meier analysis for the intent-to-treat population.

Figure B: Efficacy Table: Response rate by prior therapyPrior Therapy Subgroup

Response by RECIST v 1.0

Evaluable PatientsNKTR-102

145 mg/m2

q14d

N=31

NKTR-102

145 mg/m2

q21d

N=35TOTALN=66Prior A/T only

ORR (confirmed)

7/22 (32%) 5/21 (24%)12/43 (28%)Prior A/T in MBC

ORR (confirmed)

3/7 (43%)2/9 (22%)5/16 (31%)Prior A/T/C

ORR (confirmed)

2/6 (33%)3/10 (30%)5/16 (31%)Figure C: Efficacy Table: Response rate by tumor characteristicsDisease Subgroup

Response by RECIST v 1.0

Evaluable PatientsNKTR-102

145 mg/m2

q14d

N=31

NKTR-102

145 mg/m2

q21d

N=35TOTALN=66ER+ and/or PR+

ORR (confirmed)

8/21 (38%) 4/21 (19%)12/42 (29%)Triple-negative breast cancer

ORR (confirmed)

2/8 (25%)5/10 (50%)7/18 (39%)Visceral Disease

ORR (confirmed)

8/25 (32%)9/32 (28%)17/57 (30%)Figure D: Safety Table: Safety-Summary of Drug Related AEsMost Common Drug-related Grade 3 and 4 Adverse Events > 5% or event of interest

N (%) NKTR-102

145 mg/m2

q14d

N=35

NKTR-102

145 mg/m2

q21d

N=35Grade 3

Grade 4

Grade 3

Grade 4Diarrhea

6 (17%)

1 (3%)

8 (23%)

0Neutropenia

2 (6%)

2 (6%)

3 (9%)

1 (3%)Dehydration

3 (9%)

0

4 (11%)

0Fatigue

4 (11%)

0

3 (9%)

0Vomiting

3 (9%)

0

0

0Anaemia

1 (3%)

0

0

1 (3%)Asthenia

2 (6%)

0

0

0Lethargy

2 (6%)

0

0

0Lymphopenia

1 (3%)

1 (3%)
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
2. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
4. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
5. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
6. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
9. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
10. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
11. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 On Tuesday, July 1, ... suit in the 116 th Judicial District ... against RegenLab USA, LLC ("Defendant") for ... Relationships through false and misleading actions, fraud, ... Disparagement through libel, disparagement, defamation, misrepresentation, and ...
(Date:7/23/2014)... July 23, 2014  RT Oncology Services Corporation today ... join its board of directors. Mr. Mundie is currently ... he works on strategic projects within the company and ... chief research and strategy officer. ... RainTree, said, "Craig is a visionary technology executive. His ...
(Date:7/23/2014)... /PRNewswire-iReach/ -- Use of Risk Evaluation and Mitigation Strategies ... market entry results in $5.4 billion in lost savings ... by economic consulting firm Matrix Global Advisors ... Required by the Food and Drug Administration ... are intended to improve drug safety by ensuring that ...
Breaking Medicine Technology:Craig Mundie Joins RainTree Oncology Board of Directors 2Craig Mundie Joins RainTree Oncology Board of Directors 3New Analysis Finds $5.4 Billion In Annual Lost Savings From Strategies Geared Toward Delaying Generic Drug Entry 2
(Date:7/23/2014)... July 23, 2014 The European Vitamins ... Europe with analysis and projection of revenue. The market ... million in 2012 to $1,202.08 million by 2018, at ... Browse through the TOC of the European Vitamins Market ... provided. This also provides a glimpse of the segmentation ...
(Date:7/23/2014)... European Bio fertilizers Market Report defines and segments the ... of revenue. The bio fertilizers market in Europe is ... 2012 to $4,582.2 million by 2017, at a CAGR ... the TOC of the European Bio fertilizers Market report, ... , http://www.micromarketmonitor.com/market/europe-bio-fertilizer-4637178345.html , The bio fertilizers ...
(Date:7/23/2014)... (July 23, 2014) Statins, a class of drugs ... patient,s risk of developing Barrett,s esophagus, according to a ... , the official journal of the American Gastroenterological Association. ... with statin use. , "Patients who received statins had ... Barrett,s esophagus compared to non-users," said study author Hashem ...
(Date:7/23/2014)... to a new market research report of "Semiconductor (Silicon) ... IP), Design Architecture (Hard IP, Soft IP), Processor Type ... & Analysis to 2013 - 2020", the semiconductor (silicon) ... of 12.6% from 2014 to 2020 and reach $5.63 ... data tables with 60 figures spread through 337 pages ...
(Date:7/23/2014)... identified three genetic changes linked to an increased risk ... investigators, was published online July 20 in Nature ... the most common malignancies among women worldwide, most studies ... focused on women of European ancestry. , Given the ... Asian women and those of European ancestry, the investigators ...
Breaking Medicine News(10 mins):Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Europe Bio Fertilizer Market is Expected to Reach $4,582.2 Million in 2017 - New Report by MicroMarket Monitor 2Health News:Europe Bio Fertilizer Market is Expected to Reach $4,582.2 Million in 2017 - New Report by MicroMarket Monitor 3Health News:Europe Bio Fertilizer Market is Expected to Reach $4,582.2 Million in 2017 - New Report by MicroMarket Monitor 4Health News:Statin use decreases the risk of Barrett's esophagus 2Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 6Health News:Vanderbilt-led study identifies genes linked to breast cancer in East Asian women 2
... has found that alcohol does not kill off brain ... Queensland Brain Institute director Professor Perry Bartlett, the notion ... function similar to a napalm bomb strike, is erroneous. ... the world's top neuroscientists, claims that there is no ...
... Anderson Cancer Center have found in pre-clinical trials that ... in pancreatic cancer that shrinks or eradicates tumours, inhibits ... ,"This vehicle, or vector, is so targeted and ... used for therapy and perhaps for imaging," notes senior ...
... Residents in the United Kingdom would have to consider ... want to enjoy a pollution-free and greener future, a ... has said. ,According to the report, the ... operated cars and avoiding affordable flights. ...
... stroke patients practise daily tasks with impaired limbs, are ... Administration has approved a new robotic device called the Myomo ... arms. It is to hit the market shortly. ... weak electrical activity in patients arm muscles and providing just ...
... a new gene mutation that is associated with frontotemporal ... known as Prick's disease . ,Frontotemporal ... brain that control behaviour and language. Language problems, personality ... ,Unlike Alzheimer's disease, this Frontotemporal dementia does ...
... many of the genetic bits and pieces that drive ... disadvantages to humans or other animals. ,Nicholas ... Medicine said that the Hopkins experiments demonstrate that one ... DNA repeat elements that make up over 40 percent ...
Cached Medicine News:Health News:Gene Therapy Eradicates Pancreatic Cancer in Mice 2Health News:Brits Need to Change Lifestyle to Have a Greener Future: Report 2Health News:FDA Approve S Robotic Device to Help Stroke Patients 2Health News:FDA Approve S Robotic Device to Help Stroke Patients 3Health News:FDA Approve S Robotic Device to Help Stroke Patients 4Health News:Scientists Identify New Genetic Mutation Behind Common Dementia 2Health News:Completely Neutral Evolutionary Changes Helped Shape Our Genome 2
A system for all indications, can be used with the OrthoPilot surgical navigation system....
Electric high speed system....
The humidity chamber maintains a moist environment during immunostaining procedures as well as other laboratory procedures requiring controlled incubation steps....
Compressor-cooled plate used to keep blocks cold while sectioning....
Medicine Products: